<DOC>
	<DOCNO>NCT02273180</DOCNO>
	<brief_summary>Primary Objective : To demonstrate non-inferiority SAR342434 versus Humalog HbA1c change patient type 1 diabetes mellitus ( T1DM ) also use insulin glargine . Secondary Objectives : To assess immunogenicity SAR342434 Humalog term positive/negative status antibody titer baseline course study . To assess relationship anti-insulin antibody efficacy safety include safety extension . To assess efficacy SAR342434 Humalog term proportion patient reach target HbA1c ( &lt; 7 % ) fasting plasma glucose ( FPG ) , self-measured plasma glucose ( SMPG ) profile , insulin dose . To assess safety SAR342434 Humalog .</brief_summary>
	<brief_title>Comparison SAR342434 Humalog Rapid Acting Insulin Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine</brief_title>
	<detailed_description>The study consist : - Up 2 week screen period - 26-week treatment period - 26-week comparative safety extension period - 1-day follow-up period . - The maximum study duration 54 week per patient 1-day safety follow-up .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Lispro</mesh_term>
	<mesh_term>Insulin , Short-Acting</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Inclusion criterion : Patients T1DM diagnose least 12 month treat insulin glargine Humalog Novolog®/Novo Rapid® ( least 3 time daily meal ) 6 month prior screen visit . Written informed consent . Exclusion criterion : At screen visit , age legal age adulthood . HbA1c &lt; 7.0 % &gt; 10 % screening . Diabetes T1DM . Status post pancreatectomy . Status post pancreas and/or islet cell transplantation . Pregnancy lactation . Women childbearing potential protect highly effective contraceptive method birth control . Less 1 year continuous insulin treatment . Use insulin pump last 6 month screen visit . Use glucose lower treatment insulin include noninsulin injectable peptide last 6 month prior screen visit . Use insulin insulin glargine Humalog Novolog/Novo Rapid part multiple injection regimen ( 3 4 injection per day ) last 6 month screen visit . Liprolog® European Union approve insulin lispro allow country market . Hospitalization diabetic ketoacidosis last 6 month screen visit . Unstable proliferative diabetic retinopathy rapidly progressive diabetic retinopathy macular edema likely require treatment ( eg , laser , surgical treatment , injectable drug ) study period . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>